[Congressional Bills 107th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3014 Introduced in House (IH)]
107th CONGRESS
1st Session
H. R. 3014
To amend the Public Health Services Act to require the Director of the
National Institutes of Health to expand and intensify research
regarding Diamond-Blackfan Anemia.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
October 3, 2001
Mrs. McCarthy of New York (for herself, Mr. Grucci, Mr. Traficant, Mr.
Filner, and Mrs. Morella) introduced the following bill; which was
referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend the Public Health Services Act to require the Director of the
National Institutes of Health to expand and intensify research
regarding Diamond-Blackfan Anemia.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Diamond-Blackfan Anemia Act''.
SEC. 2. FINDINGS.
The Congress finds as follows:
(1) Diamond-Blackfan Anemia (in this section referred to as
``DBA'') is a rare genetic bone marrow failure disorder, which
develops in infancy and results in severe anemia due to failure
to make red blood cells.
(2) Treatments for DBA, including the use of steroids (such
as prednisone) and blood transfusions, have potential long-term
side effects, including osteoporosis, impaired growth because
of the steroids, and iron overload because of the transfusions.
DBA patients have an increased risk of leukemia, solid tumors,
and complete bone marrow failure.
(3) The only cure for DBA is a bone marrow transplant, a
procedure that carries serious risks and, since most patients
lack an acceptable donor, is an option for only about 25
percent of patients.
(4) Although there are a few studies focusing on other bone
marrow failure syndromes and one intramural study investigating
the efficacy of stem cell treatment for DBA patients, there are
almost no studies conducted at or with extramural funding from
the National Institutes of Health that are specifically aimed
at the identification, treatment, and cure of DBA.
SEC. 3. DIAMOND-BLACKFAN ANEMIA.
The Public Health Services Act is amended by inserting after
section 424B (42 U.S.C. 285b-7b) the following:
``diamond-blackfan anemia
``Sec. 424C. (a) In General.--The Director of the Institute, in
coordination with the National Heart, Lung, and Blood Institute and the
Office of Rare Diseases, shall expand and intensify research and
related activities of the Institute with regard to Diamond-Blackfan
Anemia.
``(b) Programs.--In carrying out subsection (a):
``(1) Scientific workshop.--The Director of the Institute
shall convene a scientific workshop for the following:
``(A) Evaluation of the state of research on
Diamond-Blackfan Anemia.
``(B) Determination of areas of importance for such
research (which may include red cell differentiation,
ribosomal protein function, cancer predisposition, and
gene discovery).
``(C) Development of a comprehensive plan for
conducting and supporting such research.
``(2) Research.--In accordance with the comprehensive plan
developed under subsection (b)(1)(C), the Director of the
Institute shall conduct or support research on the following:
``(A) The pathophysiology of Diamond-Blackfan
Anemia.
``(B) The relationship between Diamond-Blackfan
Anemia and predisposition to cancer.
``(C) Developing better treatments and ultimately a
cure for Diamond-Blackfan Anemia.
``(3) Database.--The Director of the Institute shall
facilitate the expansion and maintenance of, as well as foster
the use of, the Diamond-Blackfan Anemia National Registry.''.
<all>